. 2021 Sep 9;10:343–371. doi: 10.2147/ITT.S306103

Table 6.

Selected Trials of CAR T-Cells in Multiple Myeloma (MM)

Trial ID (References)	Treatment	Phase	Enrollment (N)	Trial Title
NCT03361748 ²¹⁹^,²⁷¹	Ide-cel	II	149	A phase II, multicenter study to determine the efficacy and safety of ide-cel in subjects with RRMM (KarMMa)
NCT03601078	Ide-cel	II	181	A phase II, multicohort, open-label, multicenter study to evaluate the efficacy and safety of ide-cel in subjects with RRMM and in subjects with clinical high-risk MM (KarMMa-2)
NCT03651128	Ide-cel vs 5 different standard of care regimens	III	381	A phase III, multicenter, randomized, open-label study to compare the efficacy and safety of ide-cel vs standard regimens in subjects with RRMM (KarMMa-3)
NCT03274219 ²²¹^,²²²^,²⁷²	bb21217	I	72	A phase I study of bb21217 in RRMM
NCT03090659 ^223–225	Cilta-cel	I/II	100	A clinical study of cilta-cel in treating RRMM
NCT03548207 ²²⁶^,²⁷³	Cilta-cel	I/II	126	A phase Ib-II, open-Label study of cilta-cel, a CAR-T therapy directed against BCMA, in subjects with RRMM (CARTITUDE-1)
NCT04133636 ²²⁸	Cilta-cel	II	160	A phase II, multicohort open-label study of cilta-cel, a CAR-T therapy directed against BCMA in subjects with MM (CARTITUDE-2)
NCT03288493 ²³²	P-BCMA-101 + Rimiducid	I/II	220	Open-label, multicenter, phase I study to assess the safety of P-BCMA-101 in subjects with RRMM followed by a Phase 2 assessment of response and safety (PRIME)
NCT03915184 ²³⁸	Zevo-cel	I	70	Open label, multi-center, phase Ib/II clinical trial to evaluate the safety and efficacy of autologous zevo-cel in patients with RRMM (LUMMICAR 2)

Abbreviations: Cilta-cel, ciltacabtagene autoleucel; Ide-cel, idecabtagene vicleucel; Zevo-cel, zevorcabtagene autoleucel.